Skip to content
lifestyle.emphas.is
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Calidi Biotherapeutics, Inc
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference
July 27, 2026
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers
July 21, 2026
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
July 20, 2026
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
July 8, 2026
Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit
June 24, 2026
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
June 23, 2026
Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study
June 16, 2026
Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights
May 14, 2026
Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston
May 13, 2026
Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI
April 29, 2026
1
2
3
Next Page
→